Ozempic (semaglutide) lowers blood sugar in type 2 diabetes by mimicking a natural gut hormone called GLP-1, which your body normally releases after eating. This hormone triggers a chain of effects: it tells the pancreas to release more insulin, stops the liver from dumping excess sugar into the bloodstream, and slows digestion so glucose enters your system more gradually. In clinical trials, people taking Ozempic saw their A1C drop by 1.5% to 1.8% over 30 to 56 weeks, a substantial improvement for most people with type 2 diabetes.
How It Works Inside Your Body
After you eat, your gut releases GLP-1, a hormone that signals the pancreas to produce insulin. In type 2 diabetes, this signaling system doesn’t work well enough on its own. Ozempic activates the same receptors that natural GLP-1 uses, but it lasts much longer in the body, which is why you only inject it once a week instead of needing it after every meal.
The drug works on blood sugar through two main pathways in the pancreas. First, it boosts insulin release, but only when blood sugar is actually elevated. This “glucose-dependent” mechanism is important because it means the drug is far less likely to cause dangerously low blood sugar compared to some older diabetes medications. Second, it suppresses glucagon, a hormone that tells your liver to release stored sugar. By dialing down glucagon, Ozempic reduces the amount of sugar your liver pushes into your bloodstream between meals and overnight, which helps bring down fasting glucose levels.
Unlike some shorter-acting GLP-1 drugs that primarily work by slowing stomach emptying, Ozempic’s main blood sugar benefits come from these insulin and glucagon effects. It does slow digestion somewhat, which contributes to feeling full longer, but that’s not the primary way it controls post-meal blood sugar spikes.
Effects on Pancreatic Health
Type 2 diabetes progressively damages the insulin-producing beta cells in the pancreas. Over time, these cells burn out, and the body makes less and less of its own insulin. A meta-analysis of 16 trials covering more than 6,500 people found that semaglutide improved beta cell function by about 50% compared to placebo or other treatments. It also reduced insulin resistance, meaning the body used its existing insulin more efficiently.
One telling marker: the ratio of proinsulin to insulin dropped by 30% in people taking semaglutide. Proinsulin is an unfinished version of insulin that struggling beta cells tend to release. A lower ratio suggests the pancreas is working more effectively, producing properly formed insulin rather than pushing out half-finished product under stress. While these findings are promising, the overall certainty of the evidence is still considered low, so it’s not yet clear how lasting these beta cell improvements are.
Heart and Kidney Protection
For people with type 2 diabetes, the biggest long-term dangers are often cardiovascular. Heart attacks and strokes kill more people with diabetes than high blood sugar itself. Semaglutide has shown a 14% reduction in major cardiovascular events, a composite that includes death from heart disease, nonfatal heart attacks, and nonfatal strokes. In a trial of over 9,600 participants, 12% of those on semaglutide experienced one of these events compared to 13.8% on placebo.
The kidney benefits are even more striking. The FLOW trial, published in the New England Journal of Medicine, found that semaglutide reduced the risk of major kidney disease events by 24%. That includes kidney failure requiring dialysis or transplant, severe drops in kidney filtration, and death from kidney or cardiovascular causes. Deaths from cardiovascular causes specifically dropped by 29%. These results are significant enough that current treatment guidelines from the American Diabetes Association now recommend GLP-1 drugs like Ozempic for people with type 2 diabetes who also have chronic kidney disease, specifically to protect both the heart and kidneys.
What to Expect With Dosing
Ozempic is a once-weekly injection you give yourself, typically in the stomach, thigh, or upper arm. The dose starts low and builds up gradually to minimize side effects. You begin at 0.25 mg weekly for four weeks. This starting dose isn’t strong enough to meaningfully control blood sugar; it’s purely to let your body adjust. After four weeks, you move up to 0.5 mg. If your blood sugar still needs more help after at least another four weeks, your dose can increase to 1 mg, which is the maximum approved dose for diabetes.
Common Side Effects and How Long They Last
Stomach-related side effects are the most common issue, and they tend to hit hardest during the first few weeks or when your dose increases. About 1 in 5 people experience nausea. Almost 1 in 10 deal with vomiting. Diarrhea affects roughly 1 in 12 people and typically resolves within about a week. Belly pain occurs in about 1 in 14 people, and constipation affects about 1 in 20, though constipation can linger for 6 to 10 weeks. Heartburn or acid reflux is less common, showing up in about 1 in 50 people.
For most people, the worst of these symptoms fades within a few weeks as the body adjusts. This is one reason the dosing schedule starts low. Eating smaller meals, avoiding high-fat foods, and not lying down right after eating can help ease nausea during the adjustment period. People who jump to higher doses too quickly tend to have more intense gut symptoms.
How It Compares to Other Diabetes Treatments
The 1.5% to 1.8% A1C reduction Ozempic delivers puts it among the most effective non-insulin options available. Metformin, the most commonly prescribed first-line medication, typically lowers A1C by about 1% to 1.5%. Older classes of drugs like sulfonylureas offer similar reductions but carry a higher risk of low blood sugar and weight gain.
Ozempic’s weight loss effect is another practical advantage. Many diabetes medications either cause weight gain or are weight-neutral, which is a problem because excess weight worsens insulin resistance. Semaglutide works on appetite centers in the brain, reducing hunger and helping people eat less naturally. For someone managing type 2 diabetes, losing even a modest amount of weight can improve blood sugar control beyond what the drug achieves through its direct hormonal effects. The combination of strong A1C lowering, weight loss, and cardiovascular and kidney protection is why GLP-1 drugs have moved to the front of treatment guidelines for many people with type 2 diabetes.